EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Mahesh Krishna iD, James Lorenzen Boyer iD

Liver International · 2026-03 · 46 (3)

DOI: 10.1111/liv.70524 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 06.02.2026. Verfasst von Mahesh Krishna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Cholestasis, Thiazepines, Organic Anion Transporters, Sodium-Dependent. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ileal bile acid transporter inhibitors (IBATi) are a new, attractive therapeutic mechanism to alter the enterohepatic circulation through depletion of the bile acid pool by blocking bile acid reuptake in the ileum leading to improvements in pruritus and liver function in cholestatic liver diseases. These drugs may also have an impact on immunity, the gut microbiome, and motility. IBATi are approved in Japan for the treatment of idiopathic chronic constipation. There are two IBATi, maralixibat and odevixibat, that have been extensively investigated in clinical trials and are FDA approved for cholestatic pruritus in progressive familial intrahepatic cholestasis and Alagille syndrome. Clinical trials exploring IBATi in other cholestatic conditions, such as biliary atresia, primary biliary cholangitis, and primary sclerosing cholangitis, are currently ongoing. In this review, we will outline the emerging data regarding the physiology and mechanism of action for the IBATi class, an overview of clinical trials that led to the approval of maralixibat and odevixibat, ongoing clinical trials in adult cholestatic liver diseases, and the future of this drug class in systemic apical sodium bile acid transporter inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisThiazepinesOrganic Anion Transporters, Sodium-DependentHumansBile Acids and SaltsAnimalsPruritusEnterohepatic CirculationMembrane GlycoproteinsMethylaminesButyratesCarrier ProteinsBenzodiazepines

Stichwörter der Autor:innen

Alagille syndromeautoimmune liver diseasebile acidsbiliary atresiacholestatic liver diseaseimmunologymicrobiomeprimary biliary cholangitisprimary sclerosing cholangitisprogressive familial intrahepatic cholestasis

Substanzen

Bile Acids and Salts3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino…odevixibatThiazepinesbile acid binding proteinsOrganic Anion Transporters, Sodium-DependentMembrane GlycoproteinsMethylaminesButyratesCarrier Proteins

Autor:innen und Institutionen

  • Department of Internal Medicine and Yale Liver Center, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Mahesh Krishna, James Lorenzen Boyer

Zitieren

APA

Krishna, M., & Boyer, J. L. (2026). Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?. Liver International, 46(3). https://doi.org/10.1111/liv.70524

Vancouver

Krishna M, Boyer JL. Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?. Liver International. 2026;46(3). doi:10.1111/liv.70524

BibTeX
@article{Krishna2026,
  author = {Krishna, Mahesh and Boyer, James Lorenzen},
  title = {Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1111/liv.70524}
}
Kostenlos starten →